Title:
COMPLEX COMPRISING PSMA-TARGETING COMPOUND LINKED TO LEAD OR THORIUM RADIONUCLIDE
Document Type and Number:
Japanese Patent JP2023178476
Kind Code:
A
Abstract:
To provide compounds that addresses challenges such as a relatively low radiobiological effectiveness (RBE) and suboptimal biodistribution.SOLUTION: The present invention relates to complexes comprising a prostate-specific membrane antigen (PSMA) targeting compound linked to a radionuclide, such as 212 Pb or 227Th, through a TCMC or DOTA chelating moiety. These compounds and pharmaceutical compositions comprising them can be used for medical applications. These applications include treatment of prostate cancer, and the complexes allow dual targeting of cancers.SELECTED DRAWING: Figure 1
Inventors:
ROY HARTVIG LARSEN
Application Number:
JP2023184091A
Publication Date:
December 14, 2023
Filing Date:
October 26, 2023
Export Citation:
Assignee:
SCIENCONS AS
International Classes:
C07D257/02; A61K51/04; A61P35/00; A61P35/04
Attorney, Agent or Firm:
Atsushi Aoki
Shinji Mihashi
Youichi Watanabe
Nakajima Masaru
Ryotaro Takei
Tatsunori Ikeda
Shinji Mihashi
Youichi Watanabe
Nakajima Masaru
Ryotaro Takei
Tatsunori Ikeda
Previous Patent: Activatable cytokine polypeptides and methods of use thereof
Next Patent: Determination of nucleic acid sequence disequilibrium
Next Patent: Determination of nucleic acid sequence disequilibrium